



Published in final edited form as:

J Alcohol Drug Depend. 2015 June ; 3(3): . doi:10.4172/2329-6488.1000e121.

Medications Discovery: Importance of Assessment of Drug Self Administration Dose-Effect Curves

Takato Hiranita*

Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079-9501, USA

There are several procedures for assessment of abuse liability/potential in laboratory animals. Among them is an intravenous (IV) drug self-administration procedure that is the gold standard. For example, the IV drug self-administration procedure has high face, predictive and construct validities [1,2]. In addition, the procedure also has lower rates of false positives and negatives, relative to other procedures [2,3]. For these reasons, the procedure has been employed for assessment of various compounds for abuse potential in humans. For example, drugs abused by humans (cocaine, methamphetamine, heroin, and ketamine) maintain self-administration responding above vehicle levels in rats [4,5]. When such a response is maintained above vehicle levels in laboratory animals, a test compound would likely be reinforcing and have abuse potential in humans.

Likewise, the IV drug self-administration procedure is also useful for assessing various compounds for medications discovery against drug abuse. For example, the opioid antagonist naltrexone can decrease self-administration responding maintained by injections of heroin [6]. When such a response is decreased, the compound “theoretically” should antagonize the reinforcing effects of the self-administered drug and could have a potential for development as an anti-abuse medication. Nonetheless, the overall conclusion is not always correct. For example, decreases in self-administration behavior can be observed with not only antagonism but with a potentiation of the reinforcing effects of the target drug. (Figure 1) shows three representative patterns of shifts in dose-effect curves of drug self-administration. Panel A indicates a leftward shift or a potentiation of the effect. In contrast, panels B and C indicate, respectively, a downward (insurmountable antagonism) and rightward shifts (surmountable antagonism). A leftward shift has been observed when the dopamine uptake inhibitor is pretreated for cocaine self-administration [7], while the dopamine receptor antagonist has been demonstrated to right-shift a dose-effect curve of cocaine self-administration [4]. Further, insurmountable antagonism has been shown when the mu opioid agonist (\pm)-methadone was pretreated for heroin self-administration [5]. Importantly, decreases in self-administration responding are observed in each descending

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Takato Hiranita, Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079-9501, USA, Tel: 870-543-6823; Fax: 870-543-7745; Takato.hiranita@fda.hhs.gov.

Declaration of Interests

None declared.

limb for all three of the patterns. Thus, it is essential to keep in mind that decreases in drug reinforcement could result from antagonism as well as a potentiation.

In summary, it is very important to assess a drug self-administration dose-effect curve including both the ascending and descending limbs, in order to fully assess compounds for anti-abuse medications discovery. Assessment of an entire dose-effect curve might be time-consuming if a single dose per session design is used. However, recent studies indicate the feasibility of a within-session, within-subject design for various drugs of abuse across pharmacological classes [5,8] and across laboratories [9-11].

Acknowledgments

The present work was supported by the Division of Neurotoxicology/ NCTR/U.S. FDA. The information in the present article is not a formal dissemination of information by the FDA and does not represent agency position or policy.

References

1. Johanson CE, Balster RL. A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. *Bull Narc.* 1978; 30:43–54. [PubMed: 36945]
2. Horton DB, Potter DM, Mead AN. A translational pharmacology approach to understanding the predictive value of abuse potential assessments. *Behav Pharmacol.* 2013; 24:410–436. [PubMed: 23873088]
3. Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? *Psychopharmacology (Berl).* 2000; 153:31–43. [PubMed: 11255927]
4. Hiranita T, Mereu M, Soto PL, Tanda G, Katz JL. Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists. *Neuropsychopharmacology.* 2013; 38:605–615. [PubMed: 23187725]
5. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, et al. Preclinical efficacy of N-substituted benztrapine analogs as antagonists of methamphetamine self-administration in rats. *J Pharmacol Exp Ther.* 2014; 348:174–191. [PubMed: 24194527]
6. Hiranita T, Soto PL, Tanda G, Kopajtic TA, Katz JL. Stimulants as specific inducers of dopamine-independent Δ^1 agonist self-administration in rats. *J Pharmacol Exp Ther.* 2013; 347:20–29. [PubMed: 23908387]
7. Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, et al. Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and Δ^1 receptors. *J Pharmacol Exp Ther.* 2011; 339:662–677. [PubMed: 21859929]
8. Hiranita T, Soto PL, Newman AH, Katz JL. Assessment of reinforcing effects of benztrapine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. *J Pharmacol Exp Ther.* 2009; 329:677–686. [PubMed: 19228996]
9. Barrett AC, Miller JR, Dohrmann JM, Caine SB. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. *Neuropharmacology.* 2004; 47(Suppl 1):256–273. [PubMed: 15464142]
10. Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, et al. Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. *Neuropsychopharmacology.* 2012; 37:1092–1103. [PubMed: 21993206]
11. Hiranita T, Wilkinson DS, Hong WC, Zou MF, Kopajtic TA, et al. 2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. *J Pharmacol Exp Ther.* 2014; 349:297–309. [PubMed: 24518035]




Figure 1. Three representative patterns of shifts in dose-effect curves of drug self administration. Lines indicate basal dose-effect curves. Dashed lines indicate dose-effect curves when pretreated. Panel A. a leftward shift. Panel B. a downward shift. Panel C. a rightward shift.